Pharmaron Beijing's net profit attributable to shareholders for the first quarter was 335 million yuan, an increase of 9.75% year-on-year.
Kanglong Biochem (03759) announced its performance for the first quarter of 2026, with operating income of 3.578 billion yuan, a year-on-year increase of 15.48%; net profit attributable to the shareholders of the listed company was 335 million yuan, a year-on-year increase of 9.75%; basic earnings per share were 0.186 yuan.
Pharmaron Beijing (03759) announced its financial performance for the first quarter of 2026, with operating income of 3.578 billion yuan, a year-on-year growth of 15.48%; net profit attributable to shareholders of the listed company was 335 million yuan, a year-on-year growth of 9.75%; basic earnings per share were 0.186 yuan.
Related Articles
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.
UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.
LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.
UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.
LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
